Rheumatoid Arthritis Patients Have Better Outcomes Than Non-Rheumatoid Arthritis Patients When Hospitalized for Ischemic Stroke: Analysis of the National Inpatient Sample.
Journal
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
ISSN: 1536-7355
Titre abrégé: J Clin Rheumatol
Pays: United States
ID NLM: 9518034
Informations de publication
Date de publication:
01 Jan 2022
01 Jan 2022
Historique:
pubmed:
15
9
2020
medline:
28
12
2021
entrez:
14
9
2020
Statut:
ppublish
Résumé
The aims of this study were to compare the outcomes of patients primarily admitted for ischemic stroke with and without a secondary diagnosis of RA. Data were abstracted from the National Inpatient Sample (NIS) 2016 and 2017 database. The NIS was searched for hospitalizations for adult patients with ischemic stroke as principal diagnosis with and without RA as secondary diagnosis using International Classification of Diseases, 10th Revision codes. The primary outcome was inpatient mortality. Hospital length of stay (LOS), total hospital charges, odds of receiving tissue plasminogen activator, and mechanical thrombectomy were secondary outcomes of interest. Multivariate logistic and linear regression analyses were used accordingly to adjust for confounders. There were more than 71 million discharges included in the combined 2016 and 2017 NIS database. Of 525,570 patients with ischemic stroke, 8670 (1.7%) had RA. Hospitalizations for ischemic stroke with RA had less inpatient mortality (4.7% vs. 5.5%; adjusted odds ratio, 0.66; 95% confidence interval, 0.52-0.85; p = 0.001), shorter LOS (5.1 vs 5.7 days, p < 0.0001), lower mean total hospital charges ($61,626 vs. $70,345, p < 0.0001), and less odds of undergoing mechanical thrombectomy (3.9% vs. 5.1%; adjusted odds ratio, 0.55; 95% confidence interval, 0.42-0.72; p < 0.0001) compared with those without RA. Hospitalizations for ischemic stroke with RA had less inpatient mortality, shorter LOS, lower total hospital charges, and less likelihood of undergoing mechanical thrombectomy compared with those without RA. However, the odds of receiving tissue plasminogen activator were similar between both groups. Further studies to understand its mechanism would be helpful.
Identifiants
pubmed: 32925445
pii: 00124743-202201000-00013
doi: 10.1097/RHU.0000000000001563
doi:
Substances chimiques
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13-e17Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet . 2010;376:1094–1108.
McInnes IB, O’Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis . 2010;69:1898–1906.
Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 Study. Ann Rheum Dis . 2014;73:1316–1322.
Truelsen T, Begg S. The Global Burden of Cerebrovascular Disease . Geneva Switzerland: World Health Organization; 2006.
Chugh C. Acute ischemic stroke: management approach. Indian J Crit Care Med . 2019;23:S140–S146.
Tiosano S, Yavne Y, Gendelman O, et al. Stroke among rheumatoid arthritis patients: does age really matter? A real-life study. Neuroepidemiology . 2017;49:99–105.
Wiseman SJ, Ralston SH, Wardlaw JM. Cerebrovascular disease in rheumatic diseases: a systematic review and meta-analysis. Stroke . 2016;47:943–950.
Nadareishvili Z, Michaud K, Hallenbeck JM, et al. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum . 2008;59:1090–1096.
Chen Y, Hsieh F, Lien L, et al. Rheumatoid arthritis significantly increased recurrence risk after ischemic stroke/transient ischemic attack. J Neurol . 2018;265:1810–1818.
Jagpal A, Navarro-Millán I. Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC Rheumatol . 2018;2:10.
Solomon DH, Goodson NJ, Katz JN, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis . 2006;65:1608–1612.
Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation . 2003;107:1303–1307.
Young A, Koduri G, Batley M, et al. Mortality in rheumatoid arthritis: increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology . 2007;46:350–357.
Meissner Y, Richter A, Manger B, et al. Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort. Ann Rheum Dis . 2017;76:1583–1590.
Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis . 2009;68:460–469.
Full LE, Monaco C. Targeting inflammation as a therapeutic strategy in accelerated atherosclerosis in rheumatoid arthritis. Cardiovasc Ther . 2011;29:231–242.
Aviña Zubieta JA, Thomas J, Sadatsafavi M, et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis . 2012;71:1524–1529.
Atzeni F, Talotta R, Masala IF, et al. Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents. Best Pract Res Clin Rheumatol . 2018;32:500–510.
Liou TH, Huang SW, Lin JW, et al. Risk of stroke in patients with rheumatism: a nationwide longitudinal population-based study. Sci Rep . 2014;4:5110.
Kahlenberg JM, Kaplan MJ. Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus. Annu Rev Med . 2013;64:249–263.
Park YB, Ahn CW, Choi HK, et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum . 2002;46:1714–1719.
Kumeda Y, Inaba M, Goto H, et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum . 2002;46:1489–1497.
Del Rincón I, O’Leary DH, Freeman GL, et al. Acceleration of atherosclerosis during the course of rheumatoid arthritis. Atherosclerosis . 2007;195:354–360.
Hannawi S, Haluska B, Marwick TH, et al. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther . 2007;9:R116.
Barbhaiya M, Solomon DH. Rheumatoid arthritis and cardiovascular disease: an update on treatment issues. Curr Opin Rheumatol . 2013;25:317–324.
Tam HW, Chen CM, Leong PY, et al. Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population-based retrospective cohort study. Int J Rheum Dis . 2018;21:1591–1599.
Dhillon N, Liang K. Prevention of stroke in rheumatoid arthritis. Curr Treat Options Neurol . 2015;17:356.
Reiss AB, Silverman A, Khalfan M, et al. Accelerated atherosclerosis in rheumatoid arthritis: mechanisms and treatment. Curr Pharm Des . 2019;25:969–986.
Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis . 2004;63:952–955.
Chen Y, Hsieh F, Chang C, et al. The effect of rheumatoid arthritis on the risk of cerebrovascular disease and coronary artery disease in young adults. J Chin Med Assoc . 2018;81:772–780.
Lai CH, Hsieh CY, Barnado A, et al. Outcomes of acute cardiovascular events in rheumatoid arthritis and systemic lupus erythematosus: a population-based study. Rheumatology (Oxford) . 2019;59:1355–1363. Available at : https://doi.org/10.1093/rheumatology/kez456 .
doi: 10.1093/rheumatology/kez456
Aviña-Zubieta JA, Choi H, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum . 2008;59:1690–1697.